President Donald Trump’s nomination of Dr. Heidi Overton to lead the Food and Drug Administration (FDA) is encouraging news for pro-life Americans. Her record suggests that after years in which pro-life concerns too often seemed secondary in the agency’s decisions, the FDA may finally have a leader prepared to align its work with the president’s commitment to protecting women and unborn children.
In public life, personnel is policy. But personnel becomes policy only when principles are translated into decisions. Overton’s confirmation hearing, therefore, offers more than an opportunity to examine her qualifications. It gives her an opportunity to define what strong pro-life leadership at the FDA will mean in practice.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
Already a member? Log in
There is good reason for optimism. Overton has written that abortion is corrosive to women, children, and society. She has criticized the expansion of abortion pills through telehealth and the mail, defended in-person medical evaluations, and argued that policymakers must protect “the two lives at stake — the woman and the baby.”
That record provides more than reassurance about her personal convictions. It supplies a standard by which pro-life Americans can understand the direction she intends to take the agency.
Mifepristone will be the first and clearest test. The abortion drug has become central to the abortion industry’s post-Roe strategy. Policies adopted under the Biden administration have permitted it to be prescribed through telehealth and shipped through the mail without requiring an ultrasound or in-person examination. Pills can also cross state lines, frustrating laws enacted by states to protect women and unborn children after Dobbs.
Overton will inherit an FDA review of real-world evidence concerning mifepristone’s safety and efficacy, including whether it can be safely dispensed under these loosened safeguards. That review was announced nearly a year ago, but remains unfinished, leaving important questions about mail-order abortion unresolved.
This delay followed a period in which the FDA’s overall direction under Commissioner Marty Makary and senior official Vinay Prasad too often appeared out of step with Trump’s pro-life commitments. Their personnel and policy decisions raised broader questions about whether protecting life would consistently guide the agency’s work. The unfinished review of whether mifepristone can be safely dispensed under these relaxed Biden-era policies became one example of that uncertainty, and its continued delay is now affecting matters far beyond the agency itself.
The consequences became even clearer at the beginning of this month, when a federal judge paused a lawsuit brought by Texas and Florida challenging the FDA’s approval and subsequent loosening of restrictions on mifepristone while the agency completes its review. The pause underscores that the unfinished review is no longer merely an internal agency matter. It is now affecting litigation, leaving states and courts waiting for clarity while women and unborn children remain subject to policies whose real-world consequences the FDA has yet to fully address.
The confirmation hearing gives Overton an opportunity to explain how she will bring that process to a responsible conclusion. That need is underscored by Chairman Bill Cassidy’s (R-LA) recent report, which found gaps in industry oversight and raised questions about how many serious complications go unreported after federal reporting requirements were weakened.
Pro-life Americans deserve to know whether the review will proceed with urgency, whether its findings will be made transparent, and whether the agency will confront these gaps. The FDA should also determine whether mail-order distribution and the absence of an in-person examination adequately protect women from medical risks, coercion, and abuse.
Mifepristone may be the immediate test, but it is not the full measure of the job. The FDA makes decisions that affect unborn children, expectant mothers, disabled Americans, the elderly, and patients seeking hope from lifesaving treatments. Those responsibilities require an agency culture that recognizes the dignity of every human life and officials willing to defend that principle when difficult decisions arise.
A pro-life ethic does not require the FDA to disregard science. It demands the opposite: honest evidence, transparent analysis, and the moral seriousness to act when human lives are at stake. Science can help the agency understand the consequences of a policy, but leadership determines whether those consequences are confronted or ignored.
Overton’s record gives pro-life Americans reason to welcome her nomination. Her hearing now offers her the chance to explain how those convictions will become a governing standard for the FDA and how she will restore accountability after a period of drift.
Strong pro-life leadership cannot end with the right principles. It must put those principles into practice.
Gary Marx is the former Executive Director of the Faith and Freedom Coalition.